2012 Movember Clinician Scientist










Prostate Cancer Canada would like to recognize the Movember Foundation as a key funder of this program.
Prostate Cancer Canada is pleased to announce the awarding of 2 Movember Clinician Scientist Awards. 

In order to decide which research projects should receive funding, each application is thoroughly reviewed by at least two cancer experts. These experts make recommendations to PCC regarding which research projects to fund. This process is called 'peer review'. The peer review process ensures that only the most meritorious research is supported. This year's successful research projects explore many different areas of prostate cancer including novel treatment therapies and the development of new tools to help better predict disease progression. 


Movember Clinician Scientist Awards

Investigator Host Institution Project Title Total Award   Award Period        
Peter Black University of British Columbia Circulating tumour cells in prostate cancer: the metastatic window $300,000  July 1, 2012- June 30, 2014
Girish Kulkarni Princess Margaret Hospital        Biopsy avoidance in patients at risk for prostate cancer and in patients with low risk prostate cancer: developing tools for personalized medicine $300,000 July 1, 2012 -
June 30, 2014









Support PSA Tests


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Prostate cancer researchers develop personalized genetic test to accurately predict recurrence risk

TORONTO, ON - November 13, 2014 – Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. More

Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer

Toronto, ON – October 27, 2014 – Prostate Cancer Canada responds today to guidelines released from The Canadian Task Force on Preventive Health Care (CTFPHC) recommending that the Prostate Specific Antigen (PSA) test should be eliminated as a screening tool for prostate cancer. More


Click here for news archive